

Registered number: 06515901

---


**MIRADA MEDICAL LIMITED**

---

**DIRECTORS' REPORT AND FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 31 DECEMBER 2019**

SATURDAY



\*A9BGZ2V7\*

A17

15/08/2020

#209

COMPANIES HOUSE

---

**MIRADA MEDICAL LIMITED**

---

**COMPANY INFORMATION**

---

**Directors**

H Bettesworth  
Prof J M Brady (resigned 1 October 2019)  
D Gudgin  
E Saragnese  
S J C Gray (appointed 13 February 2019)  
M Evans (resigned 8 February 2019)  
S G B Jantet (appointed 22 January 2020)  
D S Lawrence (appointed 1 October 2019)

**Registered number**

06515901

**Registered office**

New Barclay House  
234 Botley Road  
Oxford  
OX2 0HP

**Independent auditor**

Grant Thornton UK LLP  
Chartered Accountants & Statutory Auditor  
3140 Rowan Place  
John Smith Drive  
Oxford Business Park South  
Oxford  
OX4 2WB

**Bankers**

NatWest  
NatWest Commercial Office  
Willow Court  
West Way  
Oxford  
OX2 0JB

**Solicitors**

Blake Morgan  
Seacourt Tower  
West Way  
Oxford  
OX2 0FB

---

**MIRADA MEDICAL LIMITED**

---

**CONTENTS**

---

	Page
<b>Directors' Report</b>	1 - 2
<b>Independent Auditor's Report</b>	3 - 6
<b>Consolidated Statement of Comprehensive Income</b>	7
<b>Consolidated Statement of Financial Position</b>	8
<b>Company Statement of Financial Position</b>	9
<b>Consolidated Statement of Changes in Equity</b>	10
<b>Company Statement of Changes in Equity</b>	11 - 12
<b>Notes to the Financial Statements</b>	13 - 30

---

**MIRADA MEDICAL LIMITED**

---

**DIRECTORS' REPORT  
FOR THE YEAR ENDED 31 DECEMBER 2019**

---

The directors present their report and the financial statements for the year ended 31 December 2019.

**Principal activity**

The principal activity of the Group during the year was the development and sale of medical imaging software.

**Directors**

The directors who served during the year were:

H Bettesworth  
Prof J M Brady (resigned 1 October 2019)  
D Gudgin  
E Saragnese  
S J C Gray (appointed 13 February 2019)  
M Evans (resigned 8 February 2019)  
D S Lawrence (appointed 1 October 2019)

**Directors' responsibilities statement**

The directors are responsible for preparing the Directors' Report and the consolidated financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law, including FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs and profit or loss of the Group for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and the Group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for the maintenance and integrity of the corporate and financial information included on the Group's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

---

**MIRADA MEDICAL LIMITED**

---

**DIRECTORS' REPORT (CONTINUED)  
FOR THE YEAR ENDED 31 DECEMBER 2019**

---

**Going concern**

The loss for the year reflects the Group's continued investment in new technology and products, with investment accelerating on the back of a fund raising completed in February 2019. We had planned to raise more funds in 2021 but Covid-19 has had an impact on the Company, reducing our ability to generate new sales from the hospitals that make up most of our customer base. Whilst we've continued to generate revenue from our service base, growth has slowed. The Directors have reviewed the future prospects of the Company and prepared a cash flow covering the period until December 2021 taking into account the current pandemic and being prudent on the potential impact it may have on the company's revenue and cashflows. At this point we are already seeing the market opening up again with sales being generated in parts of the world where pandemic peaked earlier than in the UK and US. We are also seeing the US and European communication channels starting to open again which is positive.

The February 2019 funding round brought in new investment from Apposite Capital as well as the loan from Albion Capital being converted to equity. In July 2020 the Company took advantage of the Government backed Future Fund initiative and issued £4m of Convertible Loan notes to Apposite Capital and the Future Fund. The Directors are confident that with this additional support the Group has sufficient working capital for the foreseeable future and regularly review budgets and forecasts to ensure sufficient funding is in place to deliver the Company's strategy.

**Qualifying third party indemnity provisions**

The Group has maintained directors' and officers' liability insurance in respect of its directors.

**Disclosure of information to auditor**

The directors confirm that:

- so far as each director is aware, there is no relevant audit information of which the Company and the Group's auditor is unaware, and
- the directors have taken all the steps that they ought to have taken as directors in order to make themselves aware of any relevant audit information and to establish that the Company and the Group's auditor is aware of that information.

**Auditor**

The auditor, Grant Thornton UK LLP, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006.

**Small companies note**

In preparing this report, the directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.

This report was approved by the board on 12/8/2020 and signed on its behalf.

*Sebastien Jantet*

**S G B Jantet**  
Director



---

## INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF MIRADA MEDICAL LIMITED

---

### Opinion

We have audited the financial statements of Mirada Medical Limited (the 'parent Company') and its subsidiaries (the 'Group') for the year ended 31 December 2019, which comprise the Consolidated Statement of Comprehensive Income, the Consolidated and Company Statements of Financial Position, the Consolidated and Company Statement of Changes in Equity and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the Group's and of the parent Company's affairs as at 31 December 2019 and of the Group's loss for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

### Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the 'Auditor's responsibilities for the audit of the financial statements' section of our report. We are independent of the Group and the parent Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion

### The impact of macro-economic uncertainties on our audit

Our audit of the financial statements requires us to obtain an understanding of all relevant uncertainties, including those arising as a consequence of the effects of macro-economic uncertainties such as Covid-19 and Brexit. All audits assess and challenge the reasonableness of estimates made by the directors and the related disclosures and the appropriateness of the going concern basis of preparation of the financial statements. All of these depend on assessments of the future economic environment and the company's future prospects and performance.

Covid-19 and Brexit are amongst the most significant economic events currently faced by the UK, and at the date of this report their effects are subject to unprecedented levels of uncertainty, with the full range of possible outcomes and their impacts unknown. We applied a standardised firm-wide approach in response to these uncertainties when assessing the company's future prospects and performance. However, no audit should be expected to predict the unknowable factors or all possible future implications for a company associated with these particular events.



---

## INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF MIRADA MEDICAL LIMITED (CONTINUED)

---

### Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the directors' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the Group's or the parent Company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

In our evaluation of the directors' conclusions, we considered the risks associated with the company's business model, including effects arising from macro-economic uncertainties such as Covid-19 and Brexit, and analysed how those risks might affect the company's financial resources or ability to continue operations over the period of at least twelve months from the date when the financial statements are authorised for issue. In accordance with the above, we have nothing to report in these respects.

However, as we cannot predict all future events or conditions and as subsequent events may result in outcomes that are inconsistent with judgements that were reasonable at the time they were made, the absence of reference to a material uncertainty in this auditor's report is not a guarantee that the company will continue in operation.

### Other information

The directors are responsible for the other information. The other information comprises the information included in the Directors' Report, other than the financial statements and our Auditor's Report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.



---

## **INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF MIRADA MEDICAL LIMITED (CONTINUED)**

---

### **Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Directors' Report has been prepared in accordance with applicable legal requirements.

### **Matter on which we are required to report under the Companies Act 2006**

In the light of the knowledge and understanding of the Group and the parent Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Directors' Report.

### **Matters on which we are required to report by exception**

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept by the parent Company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent Company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Directors' Report and from the requirement to prepare a Group strategic report.

### **Responsibilities of directors for the financial statements**

As explained more fully in the Directors' Responsibilities Statement set out on page 1, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Group's and the parent Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or the parent Company or to cease operations, or have no realistic alternative but to do so.



---

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF MIRADA MEDICAL LIMITED (CONTINUED)**

---

**Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our Auditor's Report.

**Use of our report**

This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members as a body, for our audit work, for this report, or for the opinions we have formed.

*Grant Thornton UK LLP*

Mark Bishop FCA  
Senior Statutory Auditor  
for and on behalf of Grant Thornton UK LLP  
Statutory Auditor, Chartered Accountants  
Oxford  
Date: 12/8/2020

## MIRADA MEDICAL LIMITED

**CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME  
FOR THE YEAR ENDED 31 DECEMBER 2019**

	Note	2019 £	2018 £
Turnover	4	4,670,051	4,668,437
Cost of sales		(220,622)	(266,943)
<b>Gross profit</b>		<b>4,449,429</b>	<b>4,401,494</b>
Administrative expenses		(8,032,732)	(5,230,861)
<b>Operating loss</b>		<b>(3,583,303)</b>	<b>(829,367)</b>
Interest receivable and similar income		6,259	-
Interest payable and expenses		(33,310)	(285,558)
<b>Loss before taxation</b>		<b>(3,610,354)</b>	<b>(1,114,925)</b>
Tax on loss		690,842	390,843
<b>Loss for the financial year</b>		<b>(2,919,512)</b>	<b>(724,082)</b>
Foreign exchange on US subsidiary		31,259	(23,984)
<b>Other comprehensive income for the year</b>		<b>31,259</b>	<b>(23,984)</b>
<b>Total comprehensive income for the year</b>		<b>(2,888,253)</b>	<b>(748,066)</b>
<b>(Loss) for the year attributable to:</b>			
Owners of the parent Company		(2,919,512)	(724,082)

There were no recognised gains and losses for 2019 or 2018 other than those included in the consolidated statement of comprehensive income.

The notes on pages 13 to 30 form part of these financial statements.

**MIRADA MEDICAL LIMITED**  
**REGISTERED NUMBER:06515901**

**CONSOLIDATED STATEMENT OF FINANCIAL POSITION**  
**AS AT 31 DECEMBER 2019**

	Note	2019 £	2018 £
<b>Fixed assets</b>			
Tangible assets	9	425,774	118,119
		<u>425,774</u>	<u>118,119</u>
<b>Current assets</b>			
Debtors: amounts falling due within one year	11	2,735,186	2,168,819
Cash at bank and in hand	12	3,161,569	167,489
		<u>5,896,755</u>	<u>2,336,308</u>
Creditors: amounts falling due within one year	13	(505,345)	(616,901)
<b>Net current assets</b>		<u>5,391,410</u>	<u>1,719,407</u>
<b>Total assets less current liabilities</b>		<u>5,817,184</u>	<u>1,837,526</u>
Creditors: amounts falling due after more than one year	14	-	(2,836,023)
Deferred taxation	16	-	(8,620)
Accruals and deferred income	17	(1,876,361)	(1,568,391)
<b>Net assets/(liabilities)</b>		<u><u>3,940,823</u></u>	<u><u>(2,575,508)</u></u>
<b>Capital and reserves</b>			
Called up share capital	18	1	1
Share premium account		10,528,601	1,121,228
Capital redemption reserve		(50,320)	(50,320)
Profit and loss account		(6,537,459)	(3,646,417)
<b>Equity attributable to owners of the parent Company</b>		<u><u>3,940,823</u></u>	<u><u>(2,575,508)</u></u>

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 12/8/2020

*Sebastien Jantet*

**S G B Jantet**  
 Director

The notes on pages 13 to 30 form part of these financial statements.

**MIRADA MEDICAL LIMITED**  
**REGISTERED NUMBER:06515901**

**COMPANY STATEMENT OF FINANCIAL POSITION**  
**AS AT 31 DECEMBER 2019**

	Note	2019 £	2018 £
<b>Fixed assets</b>			
Tangible assets	9	391,177	103,490
Investments	10	61,560	61,560
		<u>452,737</u>	<u>165,050</u>
<b>Current assets</b>			
Debtors: amounts falling due within one year	11	4,616,508	3,504,646
Cash at bank and in hand	12	3,103,575	16,954
		<u>7,720,083</u>	<u>3,521,600</u>
Creditors: amounts falling due within one year	13	(455,481)	(604,328)
<b>Net current assets</b>		<u>7,264,602</u>	<u>2,917,272</u>
<b>Total assets less current liabilities</b>		<u>7,717,339</u>	<u>3,082,322</u>
Creditors: amounts falling due after more than one year	14	-	(2,836,023)
Deferred taxation	16	-	(8,620)
Accruals and deferred income	17	(1,194,197)	(939,318)
<b>Net assets/(liabilities)</b>		<u>6,523,142</u>	<u>(701,639)</u>
<b>Capital and reserves</b>			
Called up share capital	18	1	1
Share premium account		10,528,601	1,121,228
Profit and loss account		(4,005,460)	(1,822,868)
		<u>6,523,142</u>	<u>(701,639)</u>

The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

**S G B Jantet**  
 Director

*Sebastien Jantet*

Date: 12/8/2020

The notes on pages 13 to 30 form part of these financial statements.

## MIRADA MEDICAL LIMITED

**CONSOLIDATED STATEMENT OF CHANGES IN EQUITY  
FOR THE YEAR ENDED 31 DECEMBER 2019**

	Called up share capital £	Share premium account £	Investment in own shares £	Profit and loss account £	Total equity £
<b>At 1 January 2018</b>	<b>1</b>	<b>1,121,228</b>	<b>(50,320)</b>	<b>(2,904,411)</b>	<b>(1,833,502)</b>
<b>Comprehensive income for the year</b>					
Loss for the year	-	-	-	(724,082)	(724,082)
Foreign exchange on US subsidiary	-	-	-	(23,984)	(23,984)
<b>Total other comprehensive income for the year</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(23,984)</b>	<b>(23,984)</b>
<b>Total comprehensive income for the year</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(748,066)</b>	<b>(748,066)</b>
Equity-settled share option scheme	-	-	-	6,060	6,060
<b>Total transactions with owners</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>6,060</b>	<b>6,060</b>
<b>At 1 January 2019</b>	<b>1</b>	<b>1,121,228</b>	<b>(50,320)</b>	<b>(3,646,417)</b>	<b>(2,575,508)</b>
<b>Comprehensive income for the year</b>					
Loss for the year	-	-	-	(2,919,512)	(2,919,512)
Foreign exchange on US subsidiary	-	-	-	24,055	24,055
<b>Total other comprehensive income for the year</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>24,055</b>	<b>24,055</b>
<b>Total comprehensive income for the year</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(2,895,457)</b>	<b>(2,895,457)</b>
Shares issued during the year	-	9,407,373	-	-	9,407,373
Equity-settled share option scheme	-	-	-	4,415	4,415
<b>Total transactions with owners</b>	<b>-</b>	<b>9,407,373</b>	<b>-</b>	<b>4,415</b>	<b>9,411,788</b>
<b>At 31 December 2019</b>	<b>1</b>	<b>10,528,601</b>	<b>(50,320)</b>	<b>(6,537,459)</b>	<b>3,940,823</b>

The notes on pages 13 to 30 form part of these financial statements.

---

**MIRADA MEDICAL LIMITED**


---

**COMPANY STATEMENT OF CHANGES IN EQUITY  
FOR THE YEAR ENDED 31 DECEMBER 2019**


---

	Called up share capital	Share premium account	Profit and loss account	Total equity
	£	£	£	£
At 1 January 2019	1	1,121,228	(1,822,868)	(701,639)
<b>Comprehensive income for the year</b>				
Loss for the year	-	-	(2,217,723)	(2,217,723)
Foreign exchange	-	-	23,512	23,512
	-	-	(2,194,211)	(2,194,211)
<b>Total comprehensive income for the year</b>				
<b>Contributions by and distributions to owners</b>				
Shares issued during the year	-	9,407,373	-	9,407,373
Equity-settled share option scheme	-	-	11,619	11,619
	-	9,407,373	11,619	9,418,992
<b>Total transactions with owners</b>				
<b>At 31 December 2019</b>	<b>1</b>	<b>10,528,601</b>	<b>(4,005,460)</b>	<b>6,523,142</b>

---

**MIRADA MEDICAL LIMITED**

---

**COMPANY STATEMENT OF CHANGES IN EQUITY  
FOR THE YEAR ENDED 31 DECEMBER 2018**

---

	Called up share capital	Share premium account	Profit and loss account	Total equity
	£	£	£	£
At 1 January 2018	1	1,121,228	(1,304,908)	(183,679)
<b>Comprehensive income for the year</b>				
Loss for the year	-	-	(524,020)	(524,020)
	<u>-</u>	<u>-</u>	<u>(524,020)</u>	<u>(524,020)</u>
<b>Total comprehensive income for the year</b>				
<b>Contributions by and distributions to owners</b>				
Equity-settled share option scheme	-	-	6,060	6,060
	<u>-</u>	<u>-</u>	<u>6,060</u>	<u>6,060</u>
<b>Total transactions with owners</b>				
	<u>-</u>	<u>-</u>	<u>6,060</u>	<u>6,060</u>
<b>At 31 December 2018</b>	<u>1</u>	<u>1,121,228</u>	<u>(1,822,868)</u>	<u>(701,639)</u>

The notes on pages 13 to 30 form part of these financial statements.

---

**MIRADA MEDICAL LIMITED**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019**

---

**1. General information**

Mirada Medical Limited is a private company limited by shares and incorporated in England and Wales. Its registered office is located at New Barclay House, 234 Botley Road, Oxford, OX2 0HP.

**2. Accounting policies****2.1 Basis of preparation of financial statements**

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires Group management to exercise judgement in applying the Group's accounting policies (see note 3).

The Company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of Comprehensive Income in these financial statements.

The following principal accounting policies have been applied:

**2.2 Basis of consolidation**

The consolidated financial statements present the results of the Company and its own subsidiaries ("the Group") as if they form a single entity. Intercompany transactions and balances between group companies are therefore eliminated in full.

The consolidated financial statements incorporate the results of business combinations using the purchase method. In the Statement of Financial Position, the acquiree's identifiable assets, liabilities and contingent liabilities are initially recognised at their fair values at the acquisition date. The results of acquired operations are included in the Consolidated Statement of Comprehensive Income from the date on which control is obtained. They are deconsolidated from the date control ceases.

In accordance with the transitional exemption available in FRS 102, the group has chosen not to retrospectively apply the standard to business combinations that occurred before the date of transition to FRS 102, being 01 January 2015.

---

**MIRADA MEDICAL LIMITED**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019**

---

**2. Accounting policies (continued)****2.3 Going concern**

The loss for the year reflects the Group's continued investment in new technology and products, with investment accelerating on the back of a fund raising completed in February 2019. We had planned to raise more funds in 2021 but Covid-19 has had an impact on the Company, reducing our ability to generate new sales from the hospitals that make up most of our customer base. Whilst we've continued to generate revenue from our service base, growth has slowed. The Directors have reviewed the future prospects of the Company and prepared a cash flow covering the period until December 2021 taking into account the current pandemic and being prudent on the potential impact it may have on the company's revenue and cashflows. At this point we are already seeing the market opening up again with sales being generated in parts of the world where pandemic peaked earlier than in the UK and US. We are also seeing the US and European communication channels starting to open again which is positive.

The February 2019 funding round brought in new investment from Apposite Capital as well as the loan from Albion Capital being converted to equity. In July 2020 the Company took advantage of the Government backed Future Fund initiative and issued £4m of Convertible Loan notes to Apposite Capital and the Future Fund. The Directors are confident that with this additional support the Group has sufficient working capital for the foreseeable future and regularly review budgets and forecasts to ensure sufficient funding is in place to deliver the Company's strategy.

**2.4 Revenue**

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

**Rendering of services**

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:

- the amount of revenue can be measured reliably;
- it is probable that the Group will receive the consideration due under the contract;
- the stage of completion of the contract at the end of the reporting period can be measured reliably; and
- the costs incurred and the costs to complete the contract can be measured reliably.

**2.5 Intangible assets**

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

---

**MIRADA MEDICAL LIMITED**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019**

---

**2. Accounting policies (continued)****2.6 Tangible fixed assets**

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

L/Term Leasehold Property	- 20%
Equipment	- 20% - 33%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in the Consolidated Statement of Comprehensive Income.

**2.7 Valuation of investments**

Investments in subsidiaries are measured at cost less accumulated impairment.

**2.8 Debtors**

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

**2.9 Cash and cash equivalents**

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

**2.10 Financial instruments**

The Group only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or in case of an out-right short-term loan that is not at market rate, the financial asset or liability is measured, initially

---

**MIRADA MEDICAL LIMITED**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019**

---

**2. Accounting policies (continued)**

**2.10 Financial instruments (continued)**

at the present value of future cash flows discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost, unless it qualifies as a loan from a director in the case of a small company, or a public benefit entity concessionary loan.

Investments in non-derivative instruments that are equity to the issuer are measured:

- at fair value with changes recognised in the Consolidated Statement of Comprehensive Income if the shares are publicly traded or their fair value can otherwise be measured reliably;
- at cost less impairment for all other investments.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Consolidated Statement of Comprehensive Income.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

---

**MIRADA MEDICAL LIMITED**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019**

---

**2. Accounting policies (continued)**

**2.10 Financial instruments (continued)**

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Group would receive for the asset if it were to be sold at the reporting date.

Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or income as appropriate. The company does not currently apply hedge accounting for interest rate and foreign exchange derivatives.

**2.11 Creditors**

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

---

**MIRADA MEDICAL LIMITED**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019**

---

**2. Accounting policies (continued)****2.12 Foreign currency translation****Functional and presentation currency**

The Company's functional and presentational currency is GBP.

**Transactions and balances**

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Consolidated Statement of Comprehensive Income except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Consolidated Statement of Comprehensive Income within 'finance income or costs'. All other foreign exchange gains and losses are presented in the Consolidated Statement of Comprehensive Income within 'other operating income'.

On consolidation, the results of overseas operations are translated into Sterling at rates approximating to those ruling when the transactions took place. All assets and liabilities of overseas operations are translated at the rate ruling at the reporting date. Exchange differences arising on translating the opening net assets at opening rate and the results of overseas operations at actual rate are recognised in other comprehensive income.

**2.13 Finance costs**

Finance costs are charged to the Consolidated Statement of Comprehensive Income over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

**2.14 Pensions**

The Group operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Group pays fixed contributions into a separate entity. Once the contributions have been paid the Group has no further payment obligations.

The contributions are recognised as an expense in the Consolidated statement of comprehensive income when they fall due. Amounts not paid are shown in accruals as a liability in the Consolidated statement of financial position. The assets of the plan are held separately from the Group in independently administered funds.

---

**MIRADA MEDICAL LIMITED**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019**

---

**2. Accounting policies (continued)****2.15 Interest income**

Interest income is recognised in the Consolidated Statement of Comprehensive Income using the effective interest method.

**2.16 Borrowing costs**

All borrowing costs are recognised in the Consolidated Statement of Comprehensive Income in the year in which they are incurred.

**2.17 Provisions for liabilities**

Provisions are made where an event has taken place that gives the Group a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation.

Provisions are charged as an expense to the Consolidated Statement of Comprehensive Income in the year that the Group becomes aware of the obligation, and are measured at the best estimate at the Statement of Financial Position date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties.

When payments are eventually made, they are charged to the provision carried in the Statement of Financial Position.

**2.18 Current and deferred taxation**

The tax expense for the year comprises current and deferred tax. Tax is recognised in the Consolidated Statement of Comprehensive Income, except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company and the Group operate and generate income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the Statement of Financial Position date, except that:

- The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits;
- Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met; and
- Where they relate to timing differences in respect of interests in subsidiaries, associates, branches and joint ventures and the Group can control the reversal of the timing differences and such reversal is not considered probable in the foreseeable future.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

---

**MIRADA MEDICAL LIMITED**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019**

---

**2. Accounting policies (continued)****2.19 Share based payments**

The Group operates an Employee Benefit Trust (EBT) which holds shares in Mirada Medical Limited. The EBT issues equity-settled share-based payments to certain employees in consideration for services to Mirada Medical Limited.

The cost of equity-settled transactions with employees is measured by reference to the fair value at the date at which they are granted and is recognised as an expense over the vesting period which ends on the dates on which the relevant employees become fully entitled to the award. Fair value is determined using a Black-Scholes pricing model. In valuing equity-settled transactions, no account is taken of any vesting conditions other than conditions linked to the price of the shares of the Company (market conditions). No expense is recognised for awards that do not ultimately vest.

At each balance sheet date before vesting, the cumulative expense is calculated, being the extent to which the vesting period has expired and management's best estimate of the achievement or otherwise of the number of equity instruments that will ultimately vest. The movement in cumulative expense since the previous balance sheet date is recognised in the Consolidated statement of comprehensive income with a corresponding entry in equity. Where the terms of an equity-settled award are modified or a new award is designated as replacing a cancelled or settled award, the cost based on the original award terms continues to be recognised over the original vesting period. In addition, an expense is recognised over the remainder of the new vesting period for the incremental fair value of any modification, based on the difference between fair value of the original award and the fair value of the modified award, both as measured on the date of the modification, based on the difference between the fair value of the original award and the fair value of the modified award, both as measured on the date of the modification. No reduction is recognised if this difference is negative.

Where an equity-settled award is cancelled, it is treated as if it has vested on the date of cancellation and any cost not yet recognised in the income statement for the award is expensed immediately. Any compensation paid up to the fair value of the award at the cancellation or settlement date is deducted from equity, with any excess over fair value being treated as an expense in the Consolidated statement of comprehensive income.

The share option charge has arisen in respect of share options issued in and awarded to employees of Mirada Medical Limited.

In accordance with FRS 102, paragraph 35.10, section 26 of FRS 102 has not been applied to equity instruments that were granted before the date of transition to this FRS.

**2.20 Research and development**

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight line basis over their useful economic lives, which range from 3 to 6 years.

If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

---

**MIRADA MEDICAL LIMITED**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019**

---

**3. Judgements in applying accounting policies and key sources of estimation uncertainty**

When preparing the financial statements, management makes a number of judgements, estimates and assumptions about the recognition and measurement of assets, liabilities, income and expenses.

The following are significant management judgements in applying the accounting policies of the Company that have the most significant effect on the financial statements:

Trade debtors – Management applies judgement in evaluating the recoverability of debtors. Management have provided for debtors they believe will not be recovered in the financial statements.

Share options – Management applies judgement in the measurement and recognition of the equity-settled share-based payment transactions. The judgements around fair value are based on a Black-Scholes pricing model. See accounting policy 2.19 for further details of measurement.

**4. Turnover**

58% of the Company's turnover (2018: 68%) is attributable to geographical markets outside the United Kingdom.

The whole of turnover arose from the principal activity of the Group.

	2019 £	2018 £
United Kingdom	1,943,757	1,511,248
Rest of Europe	1,122,431	791,868
Rest of the world	1,603,863	2,365,321
	<u>4,670,051</u>	<u>4,668,437</u>

**5. Auditor's remuneration**

	2019 £	2018 £
Fees payable to the Group's auditor and its associates for the audit of the Group's annual financial statements	<u>21,500</u>	<u>17,100</u>

**Fees payable to the Group's auditor and its associates in respect of:**

Taxation compliance services	4,420	4,290
Other services relating to taxation	-	12,000
All other assurance services	1,500	1,300
Reward advisory services	33,750	-
	<u>39,670</u>	<u>17,590</u>

---

**MIRADA MEDICAL LIMITED**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019**

---

**6. Employees**

The average monthly number of employees, including directors, during the year was 69 (2018 - 52).

**7. Directors' remuneration**

	<b>2019</b>	<b>2018</b>
	£	£
Directors' emoluments	<b>228,119</b>	<b>180,524</b>

During the year retirement benefits were accruing to 1 director (2018: 2) in respect of defined contribution pension schemes.

**8. Intangible assets**

**Group and Company**

	<b>Goodwill</b>
	£
<b>Cost</b>	
At 1 January 2019	<b>274,693</b>
At 31 December 2019	<b>274,693</b>
<b>Amortisation</b>	
At 1 January 2019	<b>274,693</b>
At 31 December 2019	<b>274,693</b>
<b>Net book value</b>	
At 31 December 2019	-
At 31 December 2018	-

---

**MIRADA MEDICAL LIMITED**


---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019**


---

**9. Tangible fixed assets****Group**

	L/Term Leasehold Property £	Equipment £	Total £
<b>Cost or valuation</b>			
At 1 January 2019	-	492,781	492,781
Additions	237,503	149,258	386,761
At 31 December 2019	<u>237,503</u>	<u>642,039</u>	<u>879,542</u>
<b>Depreciation</b>			
At 1 January 2019	-	374,662	374,662
Charge for the year on owned assets	22,167	56,939	79,106
At 31 December 2019	<u>22,167</u>	<u>431,601</u>	<u>453,768</u>
<b>Net book value</b>			
At 31 December 2019	<u>215,336</u>	<u>210,438</u>	<u>425,774</u>
<i>At 31 December 2018</i>	<u>-</u>	<u>118,119</u>	<u>118,119</u>

## MIRADA MEDICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019

## 9. Tangible fixed assets (continued)

## Company

	L/Term Leasehold Property £	Equipment £	Total £
<b>Cost or valuation</b>			
At 1 January 2019	-	412,026	412,026
Additions	237,503	129,290	366,793
At 31 December 2019	<u>237,503</u>	<u>541,316</u>	<u>778,819</u>
<b>Depreciation</b>			
At 1 January 2019	-	308,536	308,536
Charge for the year on owned assets	22,167	56,939	79,106
At 31 December 2019	<u>22,167</u>	<u>365,475</u>	<u>387,642</u>
<b>Net book value</b>			
At 31 December 2019	<u>215,336</u>	<u>175,841</u>	<u>391,177</u>
At 31 December 2018	<u>-</u>	<u>103,490</u>	<u>103,490</u>

---

**MIRADA MEDICAL LIMITED**


---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019**


---

**10. Fixed asset investments****Company**

	<b>Investments in subsidiary companies £</b>
<b>Cost or valuation</b>	
At 1 January 2019	61,560
At 31 December 2019	<u>61,560</u>

**Subsidiary undertaking**

The following were indirect subsidiary undertakings of the Company:

<b>Name</b>	<b>Registered office</b>	<b>Holding</b>
Mirada Medical Inc	USA	100%
Mirada Medical (EBT) Limited	United Kingdom	100%

## MIRADA MEDICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019

## 11. Debtors

	Group 2019 £	Group 2018 £	Company 2019 £	Company 2018 £
Trade debtors	1,590,924	1,496,373	1,263,550	1,166,964
Amounts owed by group undertakings	-	-	2,230,475	1,683,364
Amounts owed by related parties	105,542	163,725	105,542	163,725
Other debtors	98,860	16,454	95,818	16,454
Prepayments and accrued income	279,733	145,977	260,996	127,849
Tax recoverable	660,127	346,290	660,127	346,290
	<u>2,735,186</u>	<u>2,168,819</u>	<u>4,616,508</u>	<u>3,504,646</u>

## 12. Cash and cash equivalents

	Group 2019 £	Group 2018 £	Company 2019 £	Company 2018 £
Cash at bank and in hand	3,161,569	167,489	3,103,575	16,954
Less: bank overdrafts	-	(41,747)	-	(41,747)
	<u>3,161,569</u>	<u>125,742</u>	<u>3,103,575</u>	<u>(24,793)</u>

## 13. Creditors: Amounts falling due within one year

	Group 2019 £	Group 2018 £	Company 2019 £	Company 2018 £
Bank overdrafts	-	41,747	-	41,747
Trade creditors	256,118	235,918	223,002	224,285
Amounts owed to related parties	8,250	9,266	8,250	9,266
Other taxation and social security	224,453	313,446	207,705	312,506
Other creditors	16,524	16,524	16,524	16,524
	<u>505,345</u>	<u>616,901</u>	<u>455,481</u>	<u>604,328</u>

**MIRADA MEDICAL LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019**

**14. Creditors: Amounts falling due after more than one year**

	<b>Group 2019 £</b>	<i>Group 2018 £</i>	<b>Company 2019 £</b>	<i>Company 2018 £</i>
Other creditors	-	2,836,023	-	2,836,023

The loan accrues interest at a rate of 7.5% per annum, as well as a 35% redemption premium payable on repayment of the loan balance. The loan is secured by charges over the assets of the Company.

The loan was converted to equity during the year. See note 18.

**15. Financial instruments**

	<b>Group 2019 £</b>	<i>Group 2018 £</i>	<b>Company 2019 £</b>	<i>Company 2018 £</i>
<b>Financial assets</b>				
Cash at bank and in hand	<b>3,161,569</b>	167,489	<b>3,103,575</b>	16,954
Trade debtors	<b>1,590,924</b>	1,496,373	<b>1,263,550</b>	1,166,964
Amounts owed by group undertakings	-	-	<b>2,185,782</b>	1,638,671
Amounts owed by EBT	-	-	<b>44,693</b>	44,693
Other debtors	<b>98,860</b>	16,454	<b>95,818</b>	16,454
	<b>4,851,353</b>	1,680,316	<b>6,693,418</b>	2,883,736
<b>Financial liabilities</b>				
Trade creditors	<b>264,368</b>	234,918	<b>231,252</b>	224,285
Amounts owed to Albion Capital	-	2,836,023	-	2,836,023
Accruals	<b>523,601</b>	361,812	<b>413,757</b>	317,568
	<b>787,969</b>	3,432,753	<b>645,009</b>	3,377,876

---

**MIRADA MEDICAL LIMITED**


---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019**


---

**16. Deferred taxation****Group**

	2019 £	2018 £
At beginning of year	(8,620)	(9,041)
Charged to profit or loss	8,620	421
<b>At end of year</b>	<b>-</b>	<b>(8,620)</b>

**Company**

	2019 £	2018 £
At beginning of year	(8,620)	(9,041)
Charged to profit or loss	8,620	421
<b>At end of year</b>	<b>-</b>	<b>(8,620)</b>

The deferred taxation balance is made up as follows:

	Group 2019 £	Group 2018 £	Company 2019 £	Company 2018 £
Accelerated capital allowances	-	(8,620)	-	(8,620)

**17. Accruals and deferred income**

	Group 2019 £	Group 2018 £	Company 2019 £	Company 2018 £
Accruals	(523,601)	(361,812)	(413,757)	(317,568)
Deferred income	(1,352,760)	(1,206,579)	(780,440)	(621,750)
	<b>(1,876,361)</b>	<b>(1,568,391)</b>	<b>(1,194,197)</b>	<b>(939,318)</b>

---

**MIRADA MEDICAL LIMITED**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019**

---

**18. Share capital**

	<b>2019</b>	<b>2018</b>
	<b>£</b>	<b>£</b>
<b>Allotted, called up and fully paid</b>		
11,198 (2018 - 11,193) Ordinary shares of £0.00005 each	1	1
2,015 (2018 - nil) A Preference shares of £0.00005 each	-	-
4,212 (2018 - nil) B Preference shares of £0.00005 each	-	-
	1	1
	1	1

There is a single class of ordinary shares. There are no restrictions on dividends and the repayment of capital.

A funding round took place in February 2019 for a total additional subscription of 4,212 B preference shares and 5 ordinary shares totalling £6,365,066. Additionally, the loan stock was converted to 2,015 A preference shares.

**19. Contingent liabilities**

There were no contingent liabilities as at 31 December 2019 or 31 December 2018.

**20. Capital commitments**

There were no capital commitments as at 31 December 2019 or 31 December 2018.

**21. Pension commitments**

The Group operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Group in an independently administered fund. The pension cost charge represents contributions payable by the Group to the fund and amounted to £241,381 (2018: £144,928). Contributions totaling £27,390 (2018: £13,139) were payable to the fund at the balance sheet date and are included in creditors.

**22. Commitments under operating leases**

The Group and the Company had no commitments under the non-cancellable operating leases as at the reporting date.

---

**MIRADA MEDICAL LIMITED**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019**

---

**23. Related party transactions**

At the year end £nil (2018: £2,836,023) was owed to Albion Capital, which the Directors consider to be a related party due to the influence of Mr D Gudgin over its affairs. The loan stock previously held by Albion Capital was converted into 2015 Series A Preference Shares during the year.

Purchases of £3,820 were made from Albion Capital in the year (2018: £27,100), to whom £nil was owed at year end (2018: £9,000), in addition to the above loan balance.

Revenue of £105,542 was recognised from MedyMatch Technology Ltd in the year (2018: £nil), from whom a balance of £105,542 was owing at year end (2018: £nil), which the Directors consider to be a related party due to the influence of Mr E Saragnese over its affairs.

Revenue of £nil was recognised from Optellum Ltd in the year (2018: £201,000), from whom a balance of £nil was owing at year end (2018: £163,725), which the Directors consider to be a related party due to the influence of Prof. J M Brady over its affairs.

Purchases of £3,750 were made from Apposite in the year (2018: £nil), to whom £nil was owed at year end (2018: £nil), which the Directors consider to be a related party due to the influence of Mr S Gray over its affairs.

Purchases of £8,250 were made from Cior Consulting in the year (2018: £nil), to whom £8,250 was owed at the year end (2018: £nil), which the Directors consider to be a related party due to the influence of Mr D Lawrence over its affairs.

There are no other related parties which require disclosure in accordance with Financial Reporting Standard 102.

**24. Post balance sheet events**

On 11th March 2020, the World Health Organisation declared the Covid-19 outbreak as a pandemic. This is a non-adjustment post balance sheet event and the impact of Covid-19 has been considered by the directors as part of the going concern assessment. Management are unable to estimate the financial affect of the impact from Covid-19.

In July 2020 the Company took advantage of the Government backed Future Fund initiative and issued £4m of Convertible Loan note to Apposite Capital and the Future Fund.